Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial
- PMID: 40387381
- PMCID: PMC12264687
- DOI: 10.1164/rccm.202410-1924OC
Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial
Abstract
Rationale: Preclinical and preliminary clinical data suggest that iloprost may improve tissue perfusion in septic shock. However, its effect on organ failure remains unclear. Objectives: To investigate whether iloprost provides organ protection in septic shock with hypoperfusion. Methods: In this multicenter, double-blind, randomized controlled trial, adults with septic shock and persistent hypoperfusion (i.e., increased capillary refill time and/or skin mottling) were randomized to receive a 48-hour intravenous infusion of iloprost or placebo. The primary outcome was the change in the Sequential Organ Failure Assessment (SOFA) score from randomization to Day 7. Secondary outcomes included mortality at Day 28, organ support-free days by Day 28, and mean daily SOFA score. Measurements and Main Results: A total of 240 patients were randomized, and 236 were included in the analysis. Median (IQR) changes in SOFA score were -4 (-7 to 7) in the iloprost group and -5 (-8 to 5) in the placebo group (median difference, 1; 95% CI, 0-3; P = 0.12). At 28 days, 48 patients (42%) had died in the iloprost group and 47 (39%) had died in the placebo group (relative risk, 1.08; 95% CI, 0.80-1.5). The median average SOFA score was 11.2 (7.4-15.9) in the iloprost group, compared with 10.5 (6.8-16.5) in the placebo group (median difference, 0.25; 95% CI, -1.1 to 1.8). Median (95% confidence interval) between-group differences in 28-day ventilation-, vasopressor-, and renal replacement therapy-free survival days were 0 (0-0), 0 (-1 to 1), and 0 (0-0), respectively. Severe adverse events occurred in 15% of patients in the iloprost group and 7% of patients in the placebo group (P = 0.06). Conclusions: Among patients with septic shock and persistent hypoperfusion, iloprost did not reduce the severity of organ failure. Clinical trial registered with www.clinicaltrials.gov (NCT03788837) and EudraCT (2018-001709-10).
Keywords: microcirculation; organ failure; prostacyclin; sepsis.
Comment in
-
Prostacyclin for Patients with Septic Shock: Promise, Progress, and Perspective.Am J Respir Crit Care Med. 2025 Jul;211(7):1116-1117. doi: 10.1164/rccm.202504-0957ED. Am J Respir Crit Care Med. 2025. PMID: 40439511 Free PMC article. No abstract available.
References
-
- McPeake J, Oakes M, Graham C, Ahmad N, Lone N, Connolly B, James Lind Alliance Sepsis PSP Steering Group Top ten research priorities for sepsis research: UK James Lind Alliance priority setting partnership. Lancet Respir Med . 2024;12:e68–e69. - PubMed
-
- De Backer D, Deutschman CS, Hellman J, Myatra SN, Ostermann M, Prescott HC, et al. Surviving Sepsis Campaign Research Committee Surviving Sepsis campaign research priorities 2023. Crit Care Med . 2024;52:268–296. - PubMed